Please login to the form below

Not currently logged in
Email:
Password:

cardiovascular diseases

This page shows the latest cardiovascular diseases news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn

Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn

This acquisition is a testament to Prothena’s pioneering work in ATTR amyloidosis and Novo Nordisk’s dedication to advancing new disease-modifying therapies for the benefit of people with cardiovascular ... diseases that are the world’s leading

Latest news

More from news
Approximately 5 fully matching, plus 100 partially matching documents found.

Latest Intelligence

  • The promise of precision medicine The promise of precision medicine

    Conditions classified as rare diseases affect a relatively small percentage of people in the world. ... In Qatar, research into genomics and precision medicine is being used to tackle diseases such as obesity, diabetes and cardiovascular disease.

  • AstraZeneca’s focus on diagnosing and managing chronic kidney disease AstraZeneca’s focus on diagnosing and managing chronic kidney disease

    As we continue to follow the science to understand the underlying mechanisms of associated cardiovascular, renal and metabolic diseases, we are working to address shared risk factors and develop solutions designed ... Joris Silon is Senior Vice President,

  • On our best behaviour On our best behaviour

    The main disease areas of focus have understandably been chronic diseases, including obesity, diabetes, cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD). ... A shift in behaviour could be very beneficial for pharma. With

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    Drug discovery is almost entirely focused on controlling protein activity to treat or cure diseases, using small-molecule or biologics to inhibit or in some cases boost the activity of a ... Big pharma and new start-ups. Arvinas recently attracted a $750m

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    He says the company is “very confident” of sustaining growth in China, and says its broad portfolio of medicines across oncology, respiratory and cardiovascular, metabolic and renal will help it achieve ... diseases, cardiovascular diseases,

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...